PITTSBURGH–(BUSINESS WIRE)–KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs, today announced preliminary clinical results from its Phase 1/1b STEALTH-001 trial evaluating intratumoral VET3-TGI alone or in combination with atezolizumab (NCT06444815) in patients with advanced solid tumors. The objective response rate (ORR) was 71% (5 of 7) in the response-evaluable cutaneous cancer subgroup and 41.7% (5 of 12)